Getting to the Heart of the Matter

Medicines Save Lives and Money

07.01.13 | By John Castellani

We often discuss in the Catalyst the challenges and promise inherent in the drug discovery process and its impact on patients. And at times talk about how medicines, when used appropriately, can be a valuable part of the solution to controlling health care costs in the U.S. But we don’t always do the best job of connecting the two.

PhRMA President and CEO John Castellani does make the connection in today’s issue of pharmaphorum.

In an opinion piece entitled “Getting to the heart of the matter: medicines save lives and money,” John discusses the exciting future of cardiovascular medicines from two perspectives: the hope that the 215 medicines in development for heart disease and stroke bring to future patients, and the potential for these therapies to eventually contribute to an accelerating body of evidence showing how medicines can lead to reduced spending on hospitalizations and surgeries for diseases such as congestive heart failure.

Please have a look at John’s piece, and as always, we welcome your thoughts.



Hide Comments

More On PhRMA — powered by PhRMApedia


Cost in Context